Pip: Welcome to Ophthalmology News USA — where the business of eye care gets the attention it probably deserved before someone had to build a whole site for it.

Mara: Today we’re covering clinical diagnosis, a major academic appointment, some serious capital moving into the space, and what this site is actually here to do. Let’s start with what’s changing at the diagnostic level.

When a Biopsy Isn’t the Answer

Pip: The question here is whether standard diagnostic assumptions about ocular mucous membrane pemphigoid are holding up — specifically, whether a biopsy is actually required to reach a confident diagnosis.

Mara: The post from Ophthalmology Advisor makes the clinical case directly: biopsy is not required for an ocular mucous membrane pemphigoid diagnosis, which has real implications for how clinicians approach this condition.

Pip: That matters because it touches documentation expectations, referral patterns, and how practices communicate with patients — the whole workflow shifts when a confirmatory procedure drops out of the standard path.

Mara: And those downstream effects land squarely in practice management territory, which is exactly why clinical updates like this belong in a business-of-eye-care conversation, not just a clinical one.

Pip: Next up, a name and a department chair seat that signals something about where academic ophthalmology is pointing itself.

A Chair Appointment Worth Watching

Pip: Leadership transitions at major academic centers aren’t just personnel news — they tend to telegraph where research priorities, training emphasis, and clinical innovation are heading for the next decade.

Mara: Duke School of Medicine announced that SriniVas Sadda will join Duke as chair of the Department of Ophthalmology, a move that positions one of the field’s prominent figures at a major academic and clinical hub.

Pip: Whoever holds that chair shapes fellowship training, research focus, and the standards that eventually filter down to practicing clinicians everywhere.

Mara: Exactly the kind of move worth tracking if you care about where the specialty’s intellectual center of gravity is shifting. Speaking of gravity — $330 million of it just landed somewhere.

Capital, Acquisitions, and the Eye Care Market

Pip: The investment story this week is hard to ignore: an ophthalmology venture raised $330 million, which is the kind of number that tends to rearrange competitive dynamics whether independent practices notice it or not.

Mara: Stat News covered that raise, and Ophthalmology Times reported separately that Bayer has acquired Perfuse Therapeutics and partnered with Iambic to expand its ophthalmology and AI capabilities — two moves that together suggest the sector is drawing serious pharmaceutical and venture attention simultaneously.

Pip: For independent practices, that combination of venture capital and pharma acquisition activity is a signal worth reading carefully.

What This Site Is Built to Do

Pip: Which brings us to the site itself — because understanding what Ophthalmology News USA is tracking is part of understanding why any of this coverage exists in one place.

Mara: The welcome post puts it plainly: “The goal is simple: give ophthalmology professionals one place to scan relevant updates without having to search across dozens of sources.” Coverage spans reimbursement, Medicare policy, practice management, retina, cataract, ASC news, and market movement.

Pip: So the diagnostic updates, the chair appointments, the nine-figure raises — they’re not separate stories. They’re the feed this site was built to aggregate.

Mara: And it’s still being built, with more feeds and editorial commentary coming. The infrastructure is catching up to the ambition.

---

Pip: Clinical workflows, academic leadership, capital concentration — eye care is a lot of moving parts for one specialty.

Mara: That’s exactly what this site is here to track. More next time.